Literature DB >> 14616995

Role of the microenvironment in chronic lymphocytic leukaemia.

Federico Caligaris-Cappio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14616995     DOI： 10.1046/j.1365-2141.2003.04679.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  47 in total

1.  Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells.

Authors:  Iris Gehrke; Rajesh Kumar Gandhirajan; Simon Jonas Poll-Wolbeck; Michael Hallek; Karl-Anton Kreuzer
Journal:  Mol Med       Date:  2011-04-14       Impact factor: 6.354

2.  miR-125b and miR-155 contribute to BCL2 repression and proliferation in response to CD40 ligand (CD154) in human leukemic B-cells.

Authors:  Shaun Willimott; Simon D Wagner
Journal:  J Biol Chem       Date:  2011-12-02       Impact factor: 5.157

3.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

5.  Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.

Authors:  Matthias Niedermeier; Bryan T Hennessy; Zachary A Knight; Marina Henneberg; Jianhua Hu; Antonina V Kurtova; William G Wierda; Michael J Keating; Kevan M Shokat; Jan A Burger
Journal:  Blood       Date:  2009-03-24       Impact factor: 22.113

6.  SIGLEC-G deficiency increases susceptibility to develop B-cell lymphoproliferative disorders.

Authors:  Giorgia Simonetti; Maria Teresa Sabrina Bertilaccio; Tania Veliz Rodriguez; Benedetta Apollonio; Antonis Dagklis; Martina Rocchi; Anna Innocenzi; Stefano Casola; Thomas H Winkler; Lars Nitschke; Maurilio Ponzoni; Federico Caligaris-Cappio; Paolo Ghia
Journal:  Haematologica       Date:  2014-05-23       Impact factor: 9.941

Review 7.  The microenvironment in mature B-cell malignancies: a target for new treatment strategies.

Authors:  Jan A Burger; Paolo Ghia; Andreas Rosenwald; Federico Caligaris-Cappio
Journal:  Blood       Date:  2009-07-27       Impact factor: 22.113

8.  AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance.

Authors:  Kumudha Balakrishnan; Jan A Burger; William G Wierda; Varsha Gandhi
Journal:  Blood       Date:  2008-10-03       Impact factor: 22.113

9.  The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells.

Authors:  Mohammad Luqman; Sha Klabunde; Karen Lin; Georgios V Georgakis; Anu Cherukuri; Jocelyn Holash; Cheryl Goldbeck; Xiaomei Xu; Edward E Kadel; Sang Hoon Lee; Sharon Lea Aukerman; Bahija Jallal; Natasha Aziz; Wen-Kai Weng; William Wierda; Susan O'Brien; Anas Younes
Journal:  Blood       Date:  2008-05-22       Impact factor: 22.113

10.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.